SPG601 granted FDA fast track designation for fragile X
The FDA granted fast track designation to Spinogenix's experimental oral therapy SPG601 to treat fragile X syndrome.| Fragile X News Today
A single dose of Spinogenix’s investigational oral therapy SPG601 led to significant reductions in a measure of abnormal brain activity among men with fragile X syndrome, according to top-line results from a Phase 2a trial. Announced by Spinogenix in a company press release, the results from the placebo-controlled Phase 2a trial (NCT06413537) were also presented […] The post SPG601 found to reduce measure of abnormal brain activity in fragile X appeared first on Fragile X News Today.| Fragile X News Today – The Web's Daily Resource for Fragile X News
The FDA granted fast track designation to Spinogenix's experimental oral therapy SPG601 to treat fragile X syndrome.| Fragile X News Today
Category archive page for News.| Fragile X News Today
Learn about fragile X syndrome, the most common cause of inherited intellectual disability and autism spectrum disorders.| Fragile X News Today
